Trademark: 79263354
Word
PHARA PHARMACEUTICAL REGULATORY AFFAIRS
Status Date
Tuesday, June 30, 2020
Registration Number
6087681
Registration Date
Tuesday, June 30, 2020
Filing Date
Friday, December 21, 2018
Published for Opposition
Tuesday, April 14, 2020
35 Business administrative consultancy with regard to the submission of New Drug Applications (NDAs) to the United States Food and Drug Administration (FDA) and Marketing Authorisation Applications (MMAs) to the EMA; business administrative services for the registration of physicians, investigations and research methods in the field of medicine, namely, updating and maintenance of information in registries; interim business management; personnel placement and recruitment; Employment recruiting services, namely, assistance relating to recruitment and placement of staff; consultancy with regard to personnel recruitment; personnel selection using psychological testing; psychological testing for the selection of personnel for the purposes of assessing professional expertise; Employment recruiting consultation, namely, assessment of personnel requirements; provision of commercial and business contact information, namely, commercial mediation in establishing business contacts between applicants and providers of medical services; lobbying for commercial purposes related to the medical and the pharmaceutical sectors by consulting with care providers in order to be able to provide the necessary customized care; organisation of events for advertising and/or commercial purposes; compilation of data files into computer databases and database management of data files; mediation and conclusion of commercial transactions for others, namely, mediation in the establishment of business contacts, including in the context of medical and pharmaceutical services; the aforesaid services also provided via telecommunications channels, including the internet; commercial-business advice for the business management of a hospital and/or clinic; consultancy regarding business organisation and business economics; business administration services; business administrative services, namely, providing office functions; business management; business organization, business economics being business information and business assistance services during commercialization and business management of a clinic, medical center being a franchise; psychological testing for the selection of personnel; professional business consultancy
The color(s) red is/are claimed as a feature of the mark.
"PHARMACEUTICAL REGULATORY AFFAIRS"
The mark consists of the stylized wording "PHARA" in red above the stylized wording "PHARMACEUTICAL REGULATORY AFFAIRS" in red.
Jan 10, 2021
Final Decision Transaction Processed By Ib
Oct 22, 2020
Generic Madrid Transaction Sent To Ib
Oct 22, 2020
Generic Madrid Transaction Created
Sep 30, 2020
Final Disposition Notice Created, To Be Sent To Ib
Jun 30, 2020
Registered-Principal Register
Apr 14, 2020
Official Gazette Publication Confirmation E-Mailed
Apr 14, 2020
Published For Opposition
Mar 25, 2020
Notification Of Notice Of Publication E-Mailed
Mar 11, 2020
Approved For Pub - Principal Register
Mar 11, 2020
Teas/Email Correspondence Entered
Mar 10, 2020
Correspondence Received In Law Office
Mar 10, 2020
Teas Request For Reconsideration Received
Mar 10, 2020
Notification Of Final Refusal Emailed
Mar 10, 2020
Final Refusal E-Mailed
Mar 10, 2020
Final Refusal Written
Feb 12, 2020
Teas/Email Correspondence Entered
Feb 11, 2020
Correspondence Received In Law Office
Feb 11, 2020
Teas Response To Office Action Received
Sep 20, 2019
Refusal Processed By Ib
Sep 5, 2019
Non-Final Action Mailed - Refusal Sent To Ib
Sep 5, 2019
Refusal Processed By Mpu
Aug 21, 2019
Non-Final Action (Ib Refusal) Prepared For Review
Aug 20, 2019
Non-Final Action Written
Aug 6, 2019
Application Filing Receipt Mailed
Jul 31, 2019
Assigned To Examiner
Jul 31, 2019
New Application Office Supplied Data Entered In Tram
Jul 27, 2019
Limitation From Original Application Entered
Jul 18, 2019
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
